New antibacterial drugs for topical ophthalmic use.
Three new antibacterial drugs have recently been approved for topical ophthalmic use. Ciprofloxacin (Ciloxan) and norfloxacin (Chibroxin) are fluoroquinolones with very broad activity spectra; both have been found to be safe and effective for the treatment of conjunctivitis. Ciprofloxacin, in the commercially available concentration (0.3%), has also been found to be a safe and effective treatment for corneal ulcers. Trimethoprim-polymyxin B (Polytrim) is a new combination product that has been used successfully for the treatment of conjunctivitis. Use of these three new drugs will significantly enhance the ability of the primary care clinician to treat bacterial infections of the cornea and conjunctiva.
Yolton
D P
DP
D002939:Ciprofloxacin / Q000627:therapeutic use; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy*; D003320:Corneal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination; D015818:Eye Infections, Bacterial / Q000188:drug therapy; D006801:Humans; D009643:Norfloxacin / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D011112:Polymyxin B / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use
D009883:Ophthalmic Solutions; D002939:Ciprofloxacin; D014295:Trimethoprim; D011112:Polymyxin B; D009643:Norfloxacin